Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.

NCT02417831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-04-27

Study results available
· View outcomes & findings →

Summary

A bio-equivalence of 2 different capsule formulations in fasted subjects

Conditions

  • Prostatic Hyperplasia

Interventions

DRUG

tamsulosin capsules

DRUG

tamsulosin HCl

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-05-31
Completion
2015-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02417831 on ClinicalTrials.gov